Overview
Sotyktu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and for the treatment of active psoriatic arthritis (PsA) in adults. Sotyktu is not recommended for use in combination with other potent immunosuppressants. Sotyktu is also known by its drug name, deucravacitinib.

Sotyktu belongs to the category of tyrosine kinase 2 (TYK2) inhibitors. Scientists believe it works by blocking TYK2, a protein involved in the immune response that contributes to inflammation and the development of psoriatic disease.

How do I take it?
Prescribing information states that Sotyktu is taken by mouth as a tablet once daily, with or without food, for the treatment of psoriatic disease. It is important to take Sotyktu exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Sotyktu include upper respiratory infections, increased blood creatine phosphokinase (a muscle enzyme), herpes simplex (cold sores), mouth ulcers, folliculitis (hair follicle inflammation), and acne.

Rare but serious side effects may include hypersensitivity reactions (such as angioedema, or severe swelling), serious infections, tuberculosis (a type of lung infection), malignancies (cancers including lymphoma), rhabdomyolysis (muscle breakdown with muscle pain or weakness), markedly elevated creatine phosphokinase levels, laboratory abnormalities (such as high triglycerides or liver enzyme changes), and risks related to Janus kinase (JAK) inhibition such as higher rates of cardiovascular events (heart attack or stroke), blood clots (deep venous thrombosis or pulmonary embolism), and increased risk of certain cancers.

For more information about this treatment, visit:
Sotyktu (Deucravacitinib) Tablets, for Oral Use — Bristol-Myers Squibb